SCHEMBL1753871

SCHEMBL1753871

CCCCCNS(=O)(=O)CCC

nearest known ligand 0.58

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
RELA Q04206 4/20 0.58
PPARA Q07869 4/20 0.56
CA2 P00918 5/20 0.52
CA1 P00915 4/20 0.52
CA12 O43570 2/20 0.52
CA7 P43166 2/20 0.52
CA14 Q9ULX7 2/20 0.52
EPHX1 P07099 1/20 0.50
CA9 Q16790 1/20 0.43
ALDH1A1 P00352 1/20 0.42
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7688181 0.98 RELA (0.61) RELAPPARACA2CA1CA12
SCHEMBL28469962 0.98 RELA (0.61) RELAPPARACA2CA1CA12
SCHEMBL11754427 0.96 RELA (0.59) RELAPPARACA2CA1CA12
SCHEMBL7039396 0.93 RELA (0.55) RELAPPARACA2CA1CA12
SCHEMBL7109328 0.93 RELA (0.55) RELAPPARACA2CA1CA12
SCHEMBL7042054 0.93 RELA (0.55) RELAPPARACA2CA1CA12
SCHEMBL5689484 0.93 CA1 (0.61) RELAPPARACA2CA1CA12
SCHEMBL4556568 0.91 RELA (0.68) RELAPPARACA2CA1CA12
SCHEMBL7687552 0.91 RELA (0.62) RELAPPARACA2CA1CA12
SCHEMBL8468160 0.88 RELA (0.71) RELAPPARACA2CA1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846710-B2 Method of preferentially inducing the biosynthesis of interferon 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-09-30 US disclosed
US-8846710-B2 Method of preferentially inducing the biosynthesis of interferon 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-09-30 US disclosed
US-8158794-B2 Hydroxyalkyl substituted imidazoquinoline compounds and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-04-17 US disclosed
US-8158794-B2 Hydroxyalkyl substituted imidazoquinoline compounds and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-04-17 US disclosed
US-20090069314-A1 Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-03-12 US disclosed
US-20090069314-A1 Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-03-12 US disclosed
US-20090030031-A1 Method of Preferentially Inducing the Biosynthesis of Interferon COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-01-29 US disclosed
US-20090030031-A1 Method of Preferentially Inducing the Biosynthesis of Interferon COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-01-29 US disclosed
WO-2002000622-A2 AMINOALCOHOL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030031-A1 Method of Preferentially Inducing the Biosynthesis of Interferon IFNG, IFNAR1, EIF2AK2 RELA 361/4885PPARA 966/4885CA2 4609/4885
US-20090069314-A1 Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods IFNG, IRF3, IFNAR1 RELA 283/4885PPARA 619/4885CA2 4684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.